Found: 7
Select item for more details and to access through your institution.
Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-24442-9
- By:
- Publication type:
- Article
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22143-x
- By:
- Publication type:
- Article
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 7, p. 1399, doi. 10.1002/ijc.34349
- By:
- Publication type:
- Article
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis.
- Published in:
- Communications Biology, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s42003-024-06899-8
- By:
- Publication type:
- Article
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.863329
- By:
- Publication type:
- Article
A low-input high resolution sequential chromatin immunoprecipitation method captures genome-wide dynamics of bivalent chromatin.
- Published in:
- Epigenetics & Chromatin, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13072-024-00527-9
- By:
- Publication type:
- Article
Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 21, p. 15571, doi. 10.3390/ijms242115571
- By:
- Publication type:
- Article